A protein that evolved long before animals developed circulatory systems appears to influence whether cancer immunotherapy works, but only when tumors manufacture it themselves. The same protein circulating in the bloodstream showed no relationship to treatment response.
Researchers at Nagoya University in Japan report that complement C3, produced locally by cancer-associated fibroblasts inside tumors, restricts the infiltration of immunosuppressive myeloid cells and improves the effectiveness of anti-PD-1 immunotherapy. Liver-derived C3 traveling through the blood had little impact, according to the work published in Nature Communications.
The finding addresses one of the central unsolved problems in oncology. Checkpoint inhibitors have transformed treatment for some patients while leaving many cancers unresponsive from the start or resistant after an initial period of control.
The Resistance Problem the Mechanism Addresses
Checkpoint inhibitors work indirectly. They do not attack tumors. They release molecular brakes that cancers exploit to switch off T cells, allowing the immune system to resume its own attack.
That design contains the vulnerability. If T cells cannot reach the tumor, or if the environment inside the tumor suppresses them once they arrive, releasing the brake accomplishes nothing.
Oncologists describe tumors as hot or cold on this basis. Hot tumors are infiltrated by immune cells and generally respond to checkpoint blockade. Cold tumors exclude or suppress immune cells and generally do not.
Immunosuppressive myeloid cells are one mechanism that keeps tumors cold. These cells accumulate in the tumor microenvironment and actively dampen T cell activity, which is why simply removing a checkpoint brake fails in their presence.
Most work on this problem has focused on the immune cells themselves or on the cancer cells. The structural cells that build the tumor's supporting tissue have received less attention, and that is where this finding locates the action.
The Function the Researchers Describe
Complement is among the oldest components of immune defense, a cascade of proteins that predates adaptive immunity and the circulatory system itself. C3 is present in organisms as simple as sponges and jellyfish, and its familiar role is tagging and destroying pathogens in blood.
"Tumors are surrounded by normal cells called fibroblasts. Until now, the role of complement C3 produced by these cancer-associated fibroblasts within tumor tissue was not known," said lead author Yuki Miyai, an assistant professor at Nagoya University's Graduate School of Medicine.
What the team describes is a different job for the same protein in a different location. C3 produced by fibroblasts within the tumor generates a degradation product called iC3b, which suppresses myeloid cell migration by signaling through complement receptor 3. The result is fewer immunosuppressive M2-like macrophages inside the tumor. Colorectal and lung tumors grown in mice engineered to lack fibroblast-derived C3 resisted anti-PD-1 therapy and showed increased M2-like macrophage infiltration.
Analysis of human lung cancer samples linked higher C3 around tumors to better outcomes with immunotherapy, extending the observation beyond animal models into patient tissue.
The researchers then tested whether the effect could be reproduced pharmacologically. Using a drug that imitates the way C3 blocks myeloid cell entry, they found that previously resistant tumors responded to immunotherapy and that survival was significantly prolonged in mice.
The local-versus-circulating distinction is the part with the most immediate practical implication. It suggests a blood test for C3 would not predict anything useful, while measuring C3 within tumor tissue might.
The Evidence Status and Its Boundaries
This is preclinical research combined with analysis of human tumor samples. The survival benefit was demonstrated in mice.
Mouse tumor models have a long record of producing immunotherapy results that do not replicate in patients. Mouse immune systems differ from human ones in meaningful ways, tumors are typically implanted rather than arising spontaneously, and the animals lack the treatment history and comorbidities that characterize real patients.
The human component is observational. Finding that lung tumors with higher local C3 had better immunotherapy outcomes establishes an association, not that C3 caused the difference. Tumors producing more C3 may differ in other respects that also predict response.
The drug used to mimic C3's effect is a research compound. Moving any such agent toward patients requires toxicity work, dose finding, and phase 1 trials before efficacy testing begins, a sequence that takes years and that most candidates do not survive.
Complement is also a system with substantial systemic functions in infection defense and inflammation, and manipulating it therapeutically carries risks that would need careful characterization. Patients with inherited complement deficiencies face elevated risk of certain bacterial infections, which indicates what is at stake in suppressing the pathway broadly rather than locally. The work was funded by Japanese government ministries and academic foundations rather than industry.
The Realistic Timeline and What Patients Should Know
No treatment is available or imminent. Nothing in this work changes any current treatment decision.
The nearer-term possibility is diagnostic rather than therapeutic. If local C3 levels in tumor tissue predict checkpoint inhibitor response, that could eventually help identify which patients are likely to benefit. That matters because these drugs carry real toxicity and substantial cost, and because they currently work in a minority of patients across many cancer types, leaving oncologists to recommend a demanding treatment without knowing who will gain from it.
Biomarker development also takes years and requires validation across independent patient cohorts before entering clinical use. It would also require a tissue sample, meaning a biopsy rather than a blood draw, which limits how often such a test could practically be repeated.
Patients currently receiving or considering checkpoint immunotherapy should base decisions on their oncologist's assessment and existing validated biomarkers. Anyone whose tumor has not responded to checkpoint blockade may want to ask about clinical trial eligibility, since trials testing combination approaches to resistance are the setting where mechanisms like this one are evaluated. ClinicalTrials.gov and a cancer center's trial office are the practical starting points.
MedicalDaily has previously covered preclinical work restoring the effectiveness of a last-resort antibiotic and research reframing a protein long blamed for dementia, both examples of laboratory findings arriving years before any clinical application.
Key Questions Answered
What did the researchers find? Complement C3 produced by fibroblasts inside tumors restricted immunosuppressive myeloid cells from entering, through a degradation product called iC3b signaling via complement receptor 3, and improved anti-PD-1 effectiveness. Circulating blood C3 from the liver had little effect.
Why does the location matter? It suggests a blood test for C3 would not predict treatment response, while measuring C3 within tumor tissue might. The same protein does different work depending on where it is produced.
What are cold and hot tumors? Hot tumors are infiltrated by immune cells and generally respond to checkpoint inhibitors. Cold tumors exclude or suppress immune cells and generally do not. Immunosuppressive myeloid cells are one mechanism keeping tumors cold.
Was a treatment tested? A research compound imitating C3's effect made previously resistant tumors respond and prolonged survival in mice. It is not a drug available to patients.
How reliable is mouse evidence in immunotherapy? Limited. Mouse immune systems differ from human ones, tumors are typically implanted rather than spontaneous, and many immunotherapy results in mice have not replicated in patients.
Does this change treatment now? No. No treatment is available, and nothing here alters current decisions. Patients should rely on their oncologist and existing validated biomarkers.
What should a patient whose cancer resisted immunotherapy do? Ask their oncologist about clinical trial eligibility. Trials testing combination approaches to checkpoint resistance are where mechanisms like this are evaluated. ClinicalTrials.gov and a cancer center trial office are starting points.
